Please assess the completion status of the following clinical trial:

Trial Title: BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Treatment naïve and treatment experienced patients (prior relapse, interferon intolerant, and \[allowed in Cohort A only\] prior partial response).~2. Chronic HCV infection of genotype 1 (GT1), sub-GT1b virus only.~3. Liver cirrhosis defined as Metavir Grade=4 or Ishak Grade =5 on liver biopsy or liver stiffness of =13 kPa on fibroscan.~Exclusion criteria:~1. HCV infection of mixed genotype (1/2, 1/3, and 1/4) or mixed sub-GT1a/1b or undefined diagnosed by genotypic testing at screening~2. Liver disease due to causes other than chronic HCV infection which may include but is not limited to hemochromatosis, Wilson's disease, or autoimmune liver diseases.~3. HIV infection~4. Patients who have been previously treated with an investigational or approved DAA

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- cohort A CPA (Type: EXPERIMENTAL): Cohort A CPA BI 207127/QD Faldaprevir Ribavirin
- cohort A CPB (Type: EXPERIMENTAL): Cohort B CPB BI 207127/QD Faldaprevir Ribavirin

Based on this trial design, predict the completion outcome and termination type (if applicable).